Our News
NAFLD vs MAFLD: could a name change impact the progression of liver disease research?
Liver disease is a serious worldwide problem linked to approximately two million deaths per year and in many cases is entirely preventable (Sumeet et al, 2019). One of the most common causes of chronic liver disease is non-alcoholic fatty liver disease (NAFLD), which...
Introducing the PhysioMimix™ OOC Multi-Organ Microphysiological System
CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip (OOC), today announced the commercial launch of its new PhysioMimix™ OOC Multi-Organ MPS. The next-generation platform combines CN Bio’s in vitro...
CN Bio awarded Innovate UK grant to develop single and multi-organ models for COVID-19 research
Funding will advance 3D lung cell culture models to accelerate drug discovery CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip, today announced it has received a grant from Innovate UK, the UK’s...
Flowing to the Beat of Your Heart
How Mimicking Blood Flow Makes Organ-on-a-Chip Technology Even More Life-like With every beat of your heart, blood rushes through your body. Some floods your arteries traveling from the lungs back to the heart. Some squeezes almost single-file, one frisbee-shaped...
How a novel in vitro Liver-on-a-Chip model of fatty liver disease is being used to help prevent a global healthcare crisis.
Obesity is a global epidemic. Up to a third of the USA’s adult population is now obese and worldwide, the prevalence of obesity has almost tripled since the 1970s. Increased obesity has triggered a wave of serious associated health conditions, notably cardiovascular...
CN Bio’s PhysioMimix™ technology receives FDA recognition
FDA publication demonstrates advantages of PhysioMimix™ in drug safety and metabolism applications, over standard techniques Represents the first co-published, peer-reviewed article between a microphysiological system provider and a regulator Characterizing the...
Life in the Fastlane
How a Partnership between the FDA and Organ-on-a-Chip Developers Has the Potential to Fast-track Drug Development From a small discovery in a research lab to a capsule on a pharmacist’s shelf – the path of drug development is a long one. Whilst scientists discover or...
CN Bio and the University of Melbourne collaborate to advance therapies for respiratory complications in recovered COVID-19 patients
CN Bio’s Lung-on-a-Chip technology will enable research into therapies to prevent interstitial lung disease and long-term lung impairment, following SARS-CoV-2 infection CN Bio, a leading cell culture company, that has developed single and multi-organ...
CN Bio to provide drug metabolism and safety toxicity testing services
Extended range of services supports accelerated drug discovery and development using predictive 3D Liver-on-Chip technology CN Bio, a leading 3D cell culture company, that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy...
CN Bio and Imperial College London Collaboration
CN Bio and Imperial College London collaborate to identify novel treatments for alcoholic hepatitis. CN Bio’s Liver-on-Chip technology to define underlying disease mechanisms and screen therapeutic targets. CN Bio, a leading cell culture company, that has developed...